Comparison of the clinical efficacies of two L‐asparaginase‐based chemotherapy regimens for newly diagnosed nasal‐type extranodal NK/T‐cell lymphoma
Abstract Background Nasal‐type extranodal natural killer (NK)/T cell lymphoma (ENKTL) is a rare and aggressive type of lymphoma. The optimal chemotherapy regimen for ENKTL has not yet been established. In this study, we compared the LVDP (L‐asparaginase, etoposide, dexamethasone, and cisplatin) and...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5708 |
| _version_ | 1827951715956031488 |
|---|---|
| author | Wanchun Wu Kexin Ren Xi Chen Na Li Qian Luo Tao Hai Huijie Zhou Liqun Zou |
| author_facet | Wanchun Wu Kexin Ren Xi Chen Na Li Qian Luo Tao Hai Huijie Zhou Liqun Zou |
| author_sort | Wanchun Wu |
| collection | DOAJ |
| description | Abstract Background Nasal‐type extranodal natural killer (NK)/T cell lymphoma (ENKTL) is a rare and aggressive type of lymphoma. The optimal chemotherapy regimen for ENKTL has not yet been established. In this study, we compared the LVDP (L‐asparaginase, etoposide, dexamethasone, and cisplatin) and GLIDE (gemcitabine, L‐asparaginase, ifosfamide, dexamethasone, and etoposide) chemotherapy regimens for the treatment of ENKTL. Methods A total of 267 patients with newly diagnosed ENKTL were included in this retrospective study. Propensity score matching (PSM) was used to adjust for confounders between the LVDP and GLIDE groups. Treatment responses, survival outcomes, and toxicities between the two groups were compared before and after PSM. Results At the end of therapy, the objective response rate (ORR) and complete response (CR) were 83.5% and 62.2%, respectively, for all patients. The ORR and CR were 85.5% and 62.2% for the LVDP group compared with 79.3% and 62.2% for the GLIDE group, respectively, and no differences between the two groups were found (ORR, p = 0.212; CR, p = 0.996). With a median 71 months follow‐up, the 5‐year progression‐free survival (PFS) and overall survival (OS) rates were 64.3% and 68.5%, respectively. The 5‐year PFS and OS were 65.6% and 70.1% for the LVDP group compared with 61.6% and 64.6% for the GLIDE group, respectively (PFS, p = 0.478; OS, p = 0162). After PSM, no significant differences in short‐term efficacy (ORR, p = 0.696; CR, p = 0.264) or long‐term efficacy (PFS, p = 0.794; OS, p = 0.867) between the two groups were identified. However, treatment‐related toxicities were milder in the LVDP group compared to the GLIDE group, even after adjusting for confounders via PSM. Conclusion In conclusion, both LVDP and GLIDE regimens are effective for the treatment of ENKTL. However, the LVDP regimen is safer than the GLIDE regimen, with milder treatment‐related toxicities. Therefore, the LVDP regimen could be a preferable option for patients with ENKTL. |
| first_indexed | 2024-04-09T13:45:34Z |
| format | Article |
| id | doaj.art-13c2fb20653e4e6d9f6fa00d2dcc5a9e |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-09T13:45:34Z |
| publishDate | 2023-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-13c2fb20653e4e6d9f6fa00d2dcc5a9e2023-05-09T04:04:18ZengWileyCancer Medicine2045-76342023-04-011289458947010.1002/cam4.5708Comparison of the clinical efficacies of two L‐asparaginase‐based chemotherapy regimens for newly diagnosed nasal‐type extranodal NK/T‐cell lymphomaWanchun Wu0Kexin Ren1Xi Chen2Na Li3Qian Luo4Tao Hai5Huijie Zhou6Liqun Zou7Department of Medical Oncology of Cancer Center West China Hospital, Sichuan University Chengdu ChinaDepartment of Medical Oncology of Cancer Center West China Hospital, Sichuan University Chengdu ChinaDepartment of Medical Oncology of Cancer Center West China Hospital, Sichuan University Chengdu ChinaDepartment of Medical Oncology of Cancer Center West China Hospital, Sichuan University Chengdu ChinaDepartment of Medical Oncology of Cancer Center West China Hospital, Sichuan University Chengdu ChinaDepartment of Medical Oncology of Cancer Center West China Hospital, Sichuan University Chengdu ChinaDepartment of Medical Oncology of Cancer Center West China Hospital, Sichuan University Chengdu ChinaDepartment of Medical Oncology of Cancer Center West China Hospital, Sichuan University Chengdu ChinaAbstract Background Nasal‐type extranodal natural killer (NK)/T cell lymphoma (ENKTL) is a rare and aggressive type of lymphoma. The optimal chemotherapy regimen for ENKTL has not yet been established. In this study, we compared the LVDP (L‐asparaginase, etoposide, dexamethasone, and cisplatin) and GLIDE (gemcitabine, L‐asparaginase, ifosfamide, dexamethasone, and etoposide) chemotherapy regimens for the treatment of ENKTL. Methods A total of 267 patients with newly diagnosed ENKTL were included in this retrospective study. Propensity score matching (PSM) was used to adjust for confounders between the LVDP and GLIDE groups. Treatment responses, survival outcomes, and toxicities between the two groups were compared before and after PSM. Results At the end of therapy, the objective response rate (ORR) and complete response (CR) were 83.5% and 62.2%, respectively, for all patients. The ORR and CR were 85.5% and 62.2% for the LVDP group compared with 79.3% and 62.2% for the GLIDE group, respectively, and no differences between the two groups were found (ORR, p = 0.212; CR, p = 0.996). With a median 71 months follow‐up, the 5‐year progression‐free survival (PFS) and overall survival (OS) rates were 64.3% and 68.5%, respectively. The 5‐year PFS and OS were 65.6% and 70.1% for the LVDP group compared with 61.6% and 64.6% for the GLIDE group, respectively (PFS, p = 0.478; OS, p = 0162). After PSM, no significant differences in short‐term efficacy (ORR, p = 0.696; CR, p = 0.264) or long‐term efficacy (PFS, p = 0.794; OS, p = 0.867) between the two groups were identified. However, treatment‐related toxicities were milder in the LVDP group compared to the GLIDE group, even after adjusting for confounders via PSM. Conclusion In conclusion, both LVDP and GLIDE regimens are effective for the treatment of ENKTL. However, the LVDP regimen is safer than the GLIDE regimen, with milder treatment‐related toxicities. Therefore, the LVDP regimen could be a preferable option for patients with ENKTL.https://doi.org/10.1002/cam4.5708clinical efficacyextranodal NK‐T‐cell lymphomaL‐asparaginaseprognosessurvivaltoxicity |
| spellingShingle | Wanchun Wu Kexin Ren Xi Chen Na Li Qian Luo Tao Hai Huijie Zhou Liqun Zou Comparison of the clinical efficacies of two L‐asparaginase‐based chemotherapy regimens for newly diagnosed nasal‐type extranodal NK/T‐cell lymphoma Cancer Medicine clinical efficacy extranodal NK‐T‐cell lymphoma L‐asparaginase prognoses survival toxicity |
| title | Comparison of the clinical efficacies of two L‐asparaginase‐based chemotherapy regimens for newly diagnosed nasal‐type extranodal NK/T‐cell lymphoma |
| title_full | Comparison of the clinical efficacies of two L‐asparaginase‐based chemotherapy regimens for newly diagnosed nasal‐type extranodal NK/T‐cell lymphoma |
| title_fullStr | Comparison of the clinical efficacies of two L‐asparaginase‐based chemotherapy regimens for newly diagnosed nasal‐type extranodal NK/T‐cell lymphoma |
| title_full_unstemmed | Comparison of the clinical efficacies of two L‐asparaginase‐based chemotherapy regimens for newly diagnosed nasal‐type extranodal NK/T‐cell lymphoma |
| title_short | Comparison of the clinical efficacies of two L‐asparaginase‐based chemotherapy regimens for newly diagnosed nasal‐type extranodal NK/T‐cell lymphoma |
| title_sort | comparison of the clinical efficacies of two l asparaginase based chemotherapy regimens for newly diagnosed nasal type extranodal nk t cell lymphoma |
| topic | clinical efficacy extranodal NK‐T‐cell lymphoma L‐asparaginase prognoses survival toxicity |
| url | https://doi.org/10.1002/cam4.5708 |
| work_keys_str_mv | AT wanchunwu comparisonoftheclinicalefficaciesoftwolasparaginasebasedchemotherapyregimensfornewlydiagnosednasaltypeextranodalnktcelllymphoma AT kexinren comparisonoftheclinicalefficaciesoftwolasparaginasebasedchemotherapyregimensfornewlydiagnosednasaltypeextranodalnktcelllymphoma AT xichen comparisonoftheclinicalefficaciesoftwolasparaginasebasedchemotherapyregimensfornewlydiagnosednasaltypeextranodalnktcelllymphoma AT nali comparisonoftheclinicalefficaciesoftwolasparaginasebasedchemotherapyregimensfornewlydiagnosednasaltypeextranodalnktcelllymphoma AT qianluo comparisonoftheclinicalefficaciesoftwolasparaginasebasedchemotherapyregimensfornewlydiagnosednasaltypeextranodalnktcelllymphoma AT taohai comparisonoftheclinicalefficaciesoftwolasparaginasebasedchemotherapyregimensfornewlydiagnosednasaltypeextranodalnktcelllymphoma AT huijiezhou comparisonoftheclinicalefficaciesoftwolasparaginasebasedchemotherapyregimensfornewlydiagnosednasaltypeextranodalnktcelllymphoma AT liqunzou comparisonoftheclinicalefficaciesoftwolasparaginasebasedchemotherapyregimensfornewlydiagnosednasaltypeextranodalnktcelllymphoma |